A randomized, double-blind, placebo-controlled trial with a novel dual noradrenergic reuptake inhibitor (NARI) and 5-HT3 antagonist: Results of a phase II 8-week study in female patients with diarrhea predominant irritable bowel syndrome (D-IBS)